EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pan-Cancer Targeted Sequencing Reveals Genomic Heterogeneity and Prognostic Subgroups in Urothelial Bladder Cancer

Dimitar Ugrinovski, Skender Saidi, Viktor Stankov, Martina Ambardjieva iD, Slavica Josifovska iD, Anne-Katrin Koehler, Joerg Gabert, Sasho Panov iD

Cancers · 22.03.2026 · 18 (6) · 1026

DOI: 10.3390/cancers18061026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 22.03.2026. Verfasst von Dimitar Ugrinovski und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Molecular Biology and Genomics, Institute of Biology, Faculty of Natural Sciences and Mathematics, Ss. Cyril and Methodius University,…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Urothelial bladder cancer (UBC) is a molecularly heterogeneous disease, and most sequencing studies have relied on bladder-specific or solid tumor-restricted panels. Whether broader pan-cancer assays provide additional clinically relevant information remains unclear.

Methods

We performed targeted next-generation sequencing using an extended gene panel on tumor samples from 100 patients with UBC treated at a tertiary center. Somatic single-nucleotide variants, small insertions/deletions, copy-number alterations, and gene co-occurrence patterns were analyzed and correlated with clinicopathological features, disease-free survival (DFS), and overall survival (OS).

Results

Recurrent alterations were identified in FGFR3 (≈50%), TP53 (≈35%), STAG2 (≈25%), and PIK3CA (≈20%), consistent with established molecular pathways in UBC. Less frequent but potentially actionable alterations, including mutations in BRCA1 and ALK, were also detected, reflecting the extended coverage of the panel. TP53 mutations were independently associated with worse OS, whereas STAG2 alterations were associated with improved OS, particularly in tumors without concurrent TP53 mutations. FGFR3 mutations showed a favorable but non-independent trend. No gene retained independent prognostic significance for DFS. Co-occurrence analysis revealed an FGFR3/PIK3CA-associated pathway and relative mutual exclusivity between FGFR3 and TP53. Copy-number alterations were modest overall. Comparison with TCGA data demonstrated a higher frequency of FGFR3 alterations in our cohort, likely reflecting the larger proportion of non–muscle-invasive tumors.

Conclusions

Pan-cancer targeted sequencing provided a comprehensive genomic landscape of UBC, capturing canonical drivers and additional alterations that may be overlooked by bladder-restricted assays. The identification of TP53 and STAG2 as prognostic markers highlights the potential value of broader genomic profiling for biologically informed risk stratification in urothelial bladder cancer.

Schlagwörter

Stichwörter der Autor:innen

FGFR3STAG2TP53bladder cancernext-generation sequencingpan-cancer panelprognosisurothelial carcinoma

Autor:innen und Institutionen

  • Laboratory for Molecular Biology and Genomics, Institute of Biology, Faculty of Natural Sciences and Mathematics, Ss. Cyril and Methodius University, 1000 Skopje, North Macedonia.
  • PathoNext GmbH, 04103 Leipzig, Germany.
  • University Clinic for Urology, Clinical Center, Medical Faculty, Ss. Cyril and Methodius University, 1000 Skopje, North Macedonia.
  • PHI University Clinic for Surgical Diseases St. Naum Ohridski, Skopje, Medical Faculty, Ss. Cyril and Methodius University, 1000 Skopje, North Macedonia.

ORCID-Profile: Martina Ambardjieva, Slavica Josifovska, Sasho Panov

Zitieren

APA

Ugrinovski, D., Saidi, S., Stankov, V., Ambardjieva, M., Josifovska, S., Koehler, A. K., Gabert, J., & Panov, S. (2026). Pan-Cancer Targeted Sequencing Reveals Genomic Heterogeneity and Prognostic Subgroups in Urothelial Bladder Cancer. Cancers, 18(6), 1026. https://doi.org/10.3390/cancers18061026

Vancouver

Ugrinovski D, Saidi S, Stankov V, Ambardjieva M, Josifovska S, Koehler AK, et al. Pan-Cancer Targeted Sequencing Reveals Genomic Heterogeneity and Prognostic Subgroups in Urothelial Bladder Cancer. Cancers. 2026;18(6):1026. doi:10.3390/cancers18061026

BibTeX
@article{Ugrinovski2026,
  author = {Ugrinovski, Dimitar and Saidi, Skender and Stankov, Viktor and Ambardjieva, Martina and Josifovska, Slavica and Koehler, Anne-Katrin and Gabert, Joerg and Panov, Sasho},
  title = {Pan-Cancer Targeted Sequencing Reveals Genomic Heterogeneity and Prognostic Subgroups in Urothelial Bladder Cancer},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {6},
  pages = {1026},
  doi = {10.3390/cancers18061026}
}
Kostenlos starten →